Tuberculosis in Pregnancy: Challenges of Immune Protection Authors: Damayanti Yengkhom, Adriana Weinberg Published: 2026 ABSTRACT AbstractTuberculosis (TB) is a leading cause of morbidity and mortality worldwide, affecting individuals of all ages and sexes. Individuals with altered immune responses, including pregnant women and people with human immunodeficiency virus (HIV) infection, are particularly vulnerable to TB. The increased risk posed by TB in these groups can be explained by the epidemiology and pathogenesis of TB and their immune responses to Mycobacterium tuberculosis. We highlight knowledge gaps that may hinder optimal treatment and prevention of TB in pregnant women with and without HIV. Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb), which mostly infects humans in nature. Although rare cases of TB have been described in other mammals, humans are the only natural reservoir. In 2024, approximately 10.7 million people were diagnosed with TB disease worldwide, including 5.8 million men, 3.7 million women, and 1.2 million children. TB is responsible for 6%–15% of maternal deaths worldwide and contributes to adverse pregnancy outcomes, such as intrauterine growth restriction, preterm birth, stillbirth, and rare congenital infection. A group at particularly high risk of TB and its complications are people with human immunodeficiency virus 1(HIV) infection (PWH). Worldwide, PWH account for 5.8% of cases of TB disease, but for a proportionally much higher (12.2%) part of TB mortality [1]. Moreover, maternal Mtb and HIV coinfections put infants at high risk of acquiring TB in early life, which increases the risk of extrapulmonary disease, particularly meningitis. In Durban, South Africa, a setting of high TB and HIV prevalence, 15% of mothers with TB transmitted the infection to their newborns within the first 3 weeks of life [2]. Infants and young children in countries of high TB endemicity receive the BCG vaccine in the first few days of life, which confers excellent protection against pediatric miliary and extrapulmonary TB but is less effective in preventing adult pulmonary disease and chronic infection. Countries with the highest TB burden also have high fertility rates and high incidence of HIV infection. This review summarizes the disproportionately high burden of TB illness in pregnant women with and without HIV infection and their immune response characteristics that explain their high vulnerability to TB. EPIDEMIOLOGY Geographic Distribution of TB Infections The World Health Organization determined that the number and proportion of TB cases worldwide was highest for the African (1.16 million, 23%), Western Pacific (1.193 million, 18%) and South-East Asian (2.06 million, 46%) regions [3]. The Southern African and South-East Asian regions also have the highest incidence of HIV and TB coinfections. Age and Sex Distribution Overall, TB diagnoses are more common in men than women, with peak incidence at 15–64 years of age [1]. Factors that contribute to the sex and age distribution include the level of environmental exposure to Mtb and the effect of sex hormones, sex chromosome–encoded genes, and sex-associated microRNAs on innate and adaptive immune responses [4]. However, in PWH the incidence of TB is higher in women than men and peaks between 18 and 44 years of age [1]. The factors explaining the relative difference in the incidence of TB diagnoses between men and women in the general population compared to PWH have not been systematically studied. This difference may arise from the higher incidence of HIV in women than men in areas of high TB endemicity, like South Africa, associated with the force of HIV infection in driving active TB infection (ATBI) [5]. Women also acquire HIV infection at a younger age than men when vulnerability to ATBI is high [6]. In addition, women with HIV may be more likely to be screened for ATBI when they come to medical attention during pregnancy than women without HIV, since HIV is known to increase the risk of ATBI. Pregnancy Globally, the prevalence of ATBI in pregnancy and postpartum in 2011 was 2.1 per 1000 people [2], but the range varied from 50 cases per 1000 pregnant women with HIV in India to 0.07 in all women in the United States [7, 8]. Table 1 summarizes the reports on the incidence or prevalence of TB in pregnant women with and without HIV published in the last 20 years. Information from earlier studies can be found in the last review of this topic published by Mathad and Gupta in 2012 [7]. In low-TB-burden settings, the incidence of TB has been generally higher in pregnant and particularly in postpartum women compared to nonpregnant women of childbearing age [11, 15, 19]. In women with HIV, the incidence of TB has been higher preconception than during pregnancy but generally also increased postpartum compared to antepartum [16]. The higher incidence of ATBI postpartum than antepartum may be explained by the decrease of T-cell regulation postpartum unmasking TB, which is supported by the observation that improved TB investigation during pregnancy increased the number of TB diagnoses antepartum [21]. However, enhanced catabolism of tryptophan on the kynurenine pathway postpartum resulting in immunosuppression may also contribute to this effect [23, 24]. Table 1.Active Tuberculosis Infection in Pregnant and Postpartum WomenStudy, First AuthorRegionStudy PopulationSample SizeHIV+, %Prevalence per 1000 People or Incidence per 1000 PYTB RiskAntepartum and/or PostpartumAntepartumPostpartumNon-PregnancyGupta, 2007 [9]IndiaHIV+ women postpartum71510050 per 1000 PYNA50 per 1000 PYNAHighKnight, 2009 [10]UKPregnant women792 193NA0.04 per 1000 people0.04 per 1000 peopleNANALowZenner, 2012 [11]UKWomen of reproductive age192 801NA0.15 per 1000 PY0.12 per 1000 PY0.2 per 1000 PY0.09 per 1000 PYLowSugarman, 2014 [2]GlobalWomen of reproductive ageNANA2.1 per 1000 peopleNANA1.7 per 1000 womenHigh and lowBekker, 2016 [12]South AfricaPregnant women8471NA9 per 1000 people5 per 1000 people4 per 1000 peopleNAHighBothamley, 2016 [13]Europe; USWomen with TB in pregnancy or preconception224NA75%30%45%24%LowEl-Messidi, 2016 [14]USPregnant women7 772 9990.10HIV− 0.26 per 1000 peopleHIV+ 4.8 per 1000 people0.26 per 1000 peopleNANALowRendell, 2016 [15]MongoliaWomen of reproductive age2 113 696NA2.3 per 1000 PYNANA1.7 per 1000 PYHighDennis, 2018 [8]USPregnant women57 393 459NA0.07 per 1000 people0.07 per 1000 peopleNANALowOdayar, 2018 [16]South AfricaHIV+ pregnant women151310026 per 1000 PY11 per 1000 PY14 per 1000 PY25 per 1000 PYHighBullarbo, 2018 [17]SwedenPregnant women from TB-endemic areas in a TST screening program902NA1.1 per 1000 people1.1 per 1000 peopleNANAHighFröberg, 2020 [18]SwedenPregnant women in an IGRA screening program58 2640.12HIV− 0.15 per 1000 peopleHIV+ 00.12 per 1000 people0.03 per 1000 peopleNALowJonsson, 2020 [19]SwedenWomen of reproductive age649 342NA0.29 per 1000 PY0.12 per 1000 PY0.17 per 1000 PY0.09 per 1000 PYLowWalles, 2021 [20]EthiopiaPregnant women183410%HIV− 0.3%HIV+ 1.7%HIV− 0.3%HIV+ 1.7%NAHIV− 4.4%HIV+ 17%HighNguenha, 2022 [21]MozambiquePregnant women299034HIV− 0.5 per 1000 PYHIV+ 13.1 per 1000 PYHIV− 0.7 per 1000 PYHIV+ 14.7 per 1000 PYHIV− 0HIV+ 9.8 per 1000 PYNAHighBåtshake, 2023 [22]SwedenPregnant women from TB-endemic areas7638NA2.1 per 1000 people1.3 per 1000 people0.8 per 1000 peopleNAHighAbbreviations: HIV+, human immunodeficiency virus positive; HIV−, human immunodeficiency virus negative; IGRA, interferon gamma release assay; NA, not available; PY, person-years; TB, tuberculosis; TST, tuberculin skin test; UK, United Kingdom; US, United States. Active Tuberculosis Infection in Pregnant and Postpartum Women Abbreviations: HIV+, human immunodeficiency virus positive; HIV−, human immunodeficiency virus negative; IGRA, interferon gamma release assay; NA, not available; PY, person-years; TB, tuberculosis; TST, tuberculin skin test; UK, United Kingdom; US, United States. IMMUNOLOGIC CHANGES OF PREGNANCY Immune responses greatly change in antepartum and postpartum women compared to nonpregnant women of reproductive age, which may contribute to the increased incidence of ATBI in pregnancy. Antepartum immune responses represent an adaptation to the implantation and growth of the allogeneic fetus. The hormonal changes that occur during pregnancy (Figure 1) have a profound effect on the immune system. The human chorionic gonadotrophin (hCG) surges in the first trimester and promotes regulatory T-cell (Treg) expansion in blood [26]. Both progesterone and estrogen, which increase throughout the pregnancy, further induce circulating Tregs [27, 28]. Progesterone also dampens systemic effector T-cell responses by binding to progesterone and glucocorticoid receptors and activating inhibitory downstream pathways [27]. In contrast, estrogen has Th1-stimulating proinflammatory activity [28]. At the end of the third trimester, the decrease in hCG, estrogen, and progesterone and the increase in prolactin with its proinflammatory effect [29] result in a gradual restoration of systemic Th1 activity. In addition to hormonal stimuli, the catabolism of tryptophan increases during pregnancy because of the elevated activity of its main catabolic enzyme, indoleamine 2,3-dioxygenase (IDO), in the placenta [30]. This results in accumulation of kynurenine and derivatives, which bind to the aryl hydrocarbon receptor on dendritic cells and T cells activating tolerogenic and regulatory programs, respectively. Studies have indicated that kynurenine levels remain elevated postpartum through a mechanism that likely involves liver enzymes [23, 24]. Immunologic adaptations of pregnancy. The upper panel shows hormonal changes in pregnancy that affect immune responses (adapted from [25]). The lower panels show immunologic characteristics antepartum and postpartum. For image description, please refer to the figure legend and surrounding text. indicates increases, For image description, please refer to the figure legend and surrounding text. indicates decreases, and For image description, please refer to the figure legend and surrounding text. indicates no change. Changes in cytokines and in kynurenine-to-tryptophan ratio (Kyn/Trp) refer to plasma levels. Abbreviations: IFN-γ, interferon gamma; IL, interleukin; TGF-β, transforming growth factor beta; Th, T helper cell; TNF-α, tumor necrosis factor alpha; Treg, regulatory T cell. Created in BioRender. Yengkhom, D. (2026) https://BioRender.com/owzsnmo. Conventional T Cells During pregnancy, the CD4+ T-cell count decreases [31], albeit it is not clear if this is a dilutional effect of pregnancy or if it involves decreased production or increased destruction. CD4+ T-cell numbers are restored postpartum. Moreover, Th1 activity, including production of interleukin (IL)-2, interferon gamma (IFN-γ), and cytotoxic granzymes, decrease throughout pregnancy, while Treg and production of IL-10 and transforming growth factor beta (TGF-β) regulatory cytokines increase. Th2 activity in blood increases during the second followed by a return to pre-pregnancy levels in the third trimester. Th17 activity does not appear to change during pregnancy. Postpartum is characterized by fully restored systemic Th1 activity and Treg return to pre-pregnancy levels. B Cells and Antibodies The number of circulating B cells decreases during pregnancy, but antibody concentrations increase [32]. Unconventional T Cells γδ T-cell frequencies in blood increase throughout the pregnancy and they display both CD107a and CD56 cytotoxicity markers, counterbalanced by the expression of PD-1 immunologic checkpoint inhibitor [33]. γδ T cells also produce regulatory cytokines in the second trimester. Invariant natural killer T (iNKT) cells and type II or nonclassical natural killer T (NKT) cells remain stable throughout all trimesters of pregnancy, and their frequency in circulation is similar to that of nonpregnant women. However, these cells produce less IFN-γ in pregnant than in nonpregnant women [34]. Mucosal-associated invariant T (MAIT) cells decrease in number in the circulation [35]. Natural Killer Cells The numbers of peripheral natural killer (NK) cells are generally elevated in early pregnancy, decrease throughout gestation, and return to pre-pregnancy levels postpartum. NK cells demonstrate enhanced responses to pathogens and tumor cells, with higher degranulation and IFN-γ production compared with nonpregnant women [36]. Together with unconventional T cells, they may play an especially important role in defense against infections antepartum. Myeloid Cells During pregnancy, neutrophils and monocytes increase and dendritic cells (DCs) decrease in number in the circulation [31]. Soluble Markers Plasma inflammatory markers are commonly used when investigating a potential diagnosis of ATBI. Thus, it is important to understand how pregnancy changes the plasma inflammatory profile. The data in literature diverge on many aspects, but there is consensus that C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), complement components, and D-dimer are elevated. There is also some agreement that IFN-γ, IL-2, and IL-12 plasma concentrations decrease during pregnancy, while tumor necrosis factor alpha (TNF-α), IL-10, and TGF-β increase in different degrees [37, 38]. IL-13 also increases, but only in the second trimester. Other cytokines maintain levels similar to pre-pregnancy or there is no agreement in their kinetics during pregnancy. MTB IMMUNOPATHOGENESIS To understand how immunologic changes of pregnancy affect the risk of ATBI, we will briefly review Mtb immunopathogenesis, emphasizing immunologic aspects affected by pregnancy. Mtb Infection Cycle Mtb is an intracellular pathogen that enters the host through the respiratory tract and initially infects alveolar macrophages and alveolar type 2 epithelial cells (Figure 2A) [39]. Inside the macrophages, the bacterium is killed in the phagolysosome or survives by preventing phagosome–lysosome fusion. This mechanism of immune evasion creates a reservoir for Mtb replication inside macrophages [39]. Alveolar macrophages migrate into the lung interstitium, where they attract myeloid and lymphoid innate immune cells [40]. These cells form early granulomas that are only partially effective in containing the infection. In fact, this early immune response may amplify the infection by allowing the bacilli to invade additional macrophages, DCs, and neutrophils. Notably, Mtb has mechanisms of evasion against neutrophil extracellular traps and reactive oxygen species normally used by neutrophils to kill bacteria [41]. The balance between immune activation and Mtb immune evasion determine the ability of Mtb to spread among the cells forming the early granulomas. Pregnancy-associated immune dysfunctions may further tip the balance in favor of the bacterium. Infected antigen-presenting cells (APCs) proceed to the draining lymph node where they prime Mtb-specific adaptive lymphocytes, which migrate to the site of bacterial replication, creating mature and more effective granulomas that block the spread of bacteria [40]. However, mature granulomas may also allow Mtb to survive in their centers [40]. If the host immune system completely circumscribes the infection, the host remains asymptomatic and develops latent TB infection (LTBI). Conversely, when bacteria overcome immune defenses, the host develops symptomatic or asymptomatic ATBI. In general, 5%–10% of infected people develop ATBI shortly after acquiring the infection and an additional 20% progress from LTBI to ATBI later on. Conversely, the host may eliminate Mtb during acute infection before the establishment of granulomas, or in the granulomas during LTBI or ATBI. Immunosuppression, including pregnancy and HIV infection, increases the likelihood of progression to ATBI, with PWH displaying a 20-fold higher risk of TB disease than people without HIV [42]. Immunopathogenesis of Mtb infection with considerations specific to pregnancy. A, Mtb infection cycle in the lung. B, Host immune response. For image description, please refer to the figure legend and surrounding text. Decreased during pregnancy. For image description, please refer to the figure legend and surrounding text. Increased during pregnancy. Abbreviations: ATBI, granuloma during active tuberculosis infection; GM-CSF, granulocyte-macrophage colony-stimulating factor; Gzm, granzyme; IFN-γ, interferon gamma; IL, interleukin; LTBI, granuloma during latent tuberculosis infection; Mtb, Mycobacterium tuberculosis; NK, natural killer cell; NOS, nitric oxide synthase; ROS, reactive oxygen species; Sterile, sterile granuloma; Tconv, conventional T cell; TGF-β, transforming growth factor beta; Th, T helper cell; TNF-α, tumor necrosis factor alpha; Treg, regulatory T cell; Tunconv, unconventional T cell. Created in BioRender. Yengkhom, D. (2026) https://BioRender.com/xervv5d. Host Immune Response The immune response to Mtb infection involves a network of innate and adaptive immune cells, many of which are modified by pregnancy and HIV infection (Figure 2B). Innate Immune Cell Response The early granulomas are characterized by a central area containing infected macrophages surrounded by innate immune cells including epithelioid and multinucleated giant cells, neutrophils, monocytes, DCs, NK cells, and unconventional T cells. NK and unconventional T cells release cytotoxic molecules, including perforin, granulysin, and granzymes, that effectively disrupt the Mtb cell membrane. They also secrete IFN-γ that activates additional immune cells [43]. Pregnancy and HIV infection downregulate these mechanisms, decreasing the ability of the host to eliminate the bacterium at this stage. The role of unconventional T cells in protection against Mtb is an area of growing interest, particularly after the demonstration that innate immune cells may develop durable memory-like responses [44, 45]. Innate immune cells have the potential to undergo clonal expansions and/or acquire epigenetic modifications that prime them against Mtb [46]. Unconventional T cells recognize Mtb peptides presented in the context of major histocompatibility complex (MHC) class I or class II molecules but also possess specific mechanisms of pathogen identification. γδ T cells are activated by phospho-antigens and unprocessed proteins on Mtb-infected cell membranes and lyse the infected cells [47]. In PWH, higher proportions of Mtb-specific γ9δ2 T cells differentiated people with LTBI from those with ATBI [48]. iNKT cells recognize Mtb phospholipids and glycolipids presented in the context of MHC-like CD1d molecules and secrete granulocyte-macrophage colony-stimulating factor and IFN-γ, boosting intracellular macrophage killing of Mtb [49]. The relatively recently discovered germline-encoded, mycolyl-reactive invariant T (GEMT) cells recognize lipid glucose monomycolate in the context of CD1b, prompting the elimination of Mtb [50]. There is currently no information on GEMT cells in the context of pregnancy or HIV infection. MAIT cells recognize microbial riboflavin derivatives presented by mucosal receptor 1 (MR1) expressed by epithelial cells and APCs, to which they respond with cytotoxicity and Th1- or Th17-like cytokine secretion [51]. Adaptive Immune Responses Mtb-specific B and T cells are activated in the draining lymph nodes by infected DCs. This process has limited efficacy due to the ability of Mtb to reduce DC function, including cytokine secretion, maturation, and antigen presentation [52], and may be further decreased by pregnancy and HIV infection. Primed B and T cells migrate to the site of infection, adding cell layers to the granulomas [53]. Th1 cells are deemed critical to the immune protection against Mtb through secretion of IFN-γ, TNF-α, and cytotoxic granules. IL-17, secreted by Th17 conventional T cells, also increases in ATBI and is deemed to contribute to protection [54]. In contrast, Th2 cytokines, such as IL-4, IL-10, and IL-13, decrease protective responses. Mtb-specific B cells may contribute to immune protection through antigen presentation and antibody secretion, but the precise mechanisms are still under investigation. Tissue destruction is counterbalanced by migration of Tregs to the site of infection [55]. The interplay of these immune cells in the granuloma determines the outcome of the infection ranging from pathogen elimination, containment of the infection with establishment of LTBI, or progression to ATBI. Host Immune Responses Used for the Diagnosis of TB The tuberculin skin test (TST), the first diagnostic modality designed to assess TB infection, exploits the host delayed-type hypersensitivity reaction to the Mtb extract. IFN-γ release assays (IGRAs) use T-cell responses against Mtb-specific early secretory antigenic target 6 kDa and culture filtrate protein 10 synthetic peptides to identify immunologic memory of the host to Mtb. Inflammatory soluble factors and gene transcription profiles in blood have been proposed for the differential diagnosis of ATBI and LTBI [56]. However, the diagnostic accuracy of these tools is predicated on the ability of the host to mount the expected immune response to Mtb, which is generally modified by pregnancy and HIV infection. EFFECT OF PREGNANCY ON IMMUNE-MEDIATED PROTECTION AND DIAGNOSIS OF MTB INFECTION The changes in frequencies and functionality of multiple immune cell subsets during the different stages of pregnancy modulate the host susceptibility to ATBI (Figure 1). The second and third trimesters of pregnancy are associated with the lowest Th1 responses increasing the risk of progression of primary Mtb infections. In women with LTBI, the increase in Tregs during pregnancy may affect the structure of the granulomas and facilitate the escape of Mtb from its containment. Compared with adults with LTBI who do not develop ATBI (nonprogressors), pregnant women with LTBI in the third trimester have lower levels of alpha 1-acid glycoprotein, IL-1β, soluble CD163, IL-6, and IL-17, which may contribute to their increased risk of progression [57]. During postpartum, the decrease in Tregs and increase in inflammatory immune responses may unmask ATBI in a similar but much less florid fashion than the immune reconstitution syndrome described in PWH [58]. The immune response may shift an asymptomatic ATBI to symptomatic ATBI. Moreover, the persistently increased catabolism of tryptophan during postpartum [23, 24] may destabilize the granulomas, as suggested by studies in nonhuman primates [59], and promote the transition from LTBI to ATBI. These mechanisms may explain the increased incidence of ATBI diagnoses in postpartum compared to antepartum reported in several studies [11, 19]. The role of antibodies in protection against TB is incompletely understood, and, therefore, it is difficult to ascertain the effect of the pregnancy-associated increased antibody production on the risk of ATBI antepartum or postpartum. As a result of decreased Th1 and other inflammatory responses antepartum, standard diagnostic tests, such as IGRA and TST, lose sensitivity, hindering the diagnosis of TB infection [60]. Furthermore, erythrocyte sedimentation rate and C-reactive protein increase during pregnancy and may become confounders in distinguishing ATBI from LTBI [61]. There is currently an effort to develop plasma cytokine, transcriptomic, and metabolomic signatures as a diagnostic tool for differentiating LTBI from ATBI [62, 63]. The accuracy of these tests during pregnancy will have to be specifically assessed. THE INTERACTION OF PREGNANCY AND HIV INFECTION ON IMMUNE PROTECTION AGAINST TB Very few studies have addressed this interaction, despite pregnant women with HIV displaying a higher incidence of ATBI than pregnant women without HIV or nonpregnant women with HIV. The effect of HIV infection on responses to Mtb has been extensively studied and recently reviewed [64]. Here, we highlight select mechanisms that may be additive or synergistic with the pregnancy-associated immunosuppression. HIV infection reduces the number of CD4+ T cells and alters their functionality. Moreover, HIV-1 has a tropism for Mtb-specific CD4+ T cells, which are reduced both in blood and in the lungs in disproportionately higher numbers than CD4+ T cells with other antigenic specificities. This observation applies both to Th1 and Th17 cells [65], compounding the decrease in Th1 activity in pregnancy. HIV infection is also associated with increased IDO activity [66] and a relative increase in the proportions of circulating Tregs that may add to the effect of pregnancy and increase the risk of progression from LTBI to ATBI. HIV infection impairs pathogen detection, phagocytosis, and microbial killing by macrophages and neutrophils [67] and decreases NK cell function [68], compromising the few immune responses important for protection against Mtb that may not be downregulated during pregnancy. Conversely, the subverting effect of HIV infection on antigen presentation by DCs and monocytes [69] may be additive to the effect of pregnancy. HIV infection decreases the number of CD4+ unconventional T cells in blood and tissues and depresses the functionality of MAIT cells by increasing the expression of PD-1, and of γδ T cells by decreasing the production of TNF-α and perforin. These changes may add to the unconventional T-cell dysregulation associated with pregnancy. The discrepancy between IGRA and TST is higher in pregnant women with HIV than in HIV-negative pregnant women, attesting to a higher perturbation of the immune responses in pregnancies complicated by HIV infection [70]. Effect of TB Preventive Treatment in High-Risk Pregnant Women Tuberculosis preventive treatment (TPT) is currently recommended for all PWH living in TB-endemic areas and those with evidence of LTBI in countries with low incidence of TB. However, the administration of isoniazid, which has been frequently used for TPT, was shown to be associated with adverse pregnancy outcomes in some studies [71]. Treatment of ATBI and TPT reduce the bacterial load, resulting in a shift in the Th1 immune response from IFN-γ to IL-2 dominance and from Th17 to Treg cells, which share the initial pathway of differentiation [72]. Moreover, treatment of ATBI and TPT decrease cytotoxic responses to Mtb [73, 74]. Thus, treatment may weaken long-term immunologic memory to Mtb, an effect that may have to be counterbalanced with the administration of effective vaccines, when they become available. CONCLUSIONS TB carries high morbidity and mortality in pregnant women, which are further increased by HIV coinfection. Pregnancy and HIV infection may have additive or even synergistic effects on the reduction of Th1 activity, increase in Tregs, and innate immune cell dysfunctions, including macrophages, compounding the decrease of immune protection against Mtb. However, the exact mechanism of immune protection against Mtb is incompletely understood in general and even more so in the context of pregnancy-specific immune adaptation requiring additional research. Areas that are particularly understudied in the context of pregnancy and Mtb infection include the role of unconventional T cells and antibodies. Moreover, the effect of TB treatment during pregnancy, particularly in the context of HIV infection, on Mtb immunologic memory also warrants further investigation.